CN114989295A - 抗MERS-CoV单克隆抗体及其应用 - Google Patents
抗MERS-CoV单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN114989295A CN114989295A CN202210694642.0A CN202210694642A CN114989295A CN 114989295 A CN114989295 A CN 114989295A CN 202210694642 A CN202210694642 A CN 202210694642A CN 114989295 A CN114989295 A CN 114989295A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- mers
- cov
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000025370 Middle East respiratory syndrome Diseases 0.000 title abstract description 43
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims abstract description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 37
- 238000000034 method Methods 0.000 abstract description 23
- 108090000623 proteins and genes Proteins 0.000 abstract description 23
- 210000004408 hybridoma Anatomy 0.000 abstract description 20
- 238000002965 ELISA Methods 0.000 abstract description 17
- 210000004027 cell Anatomy 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 238000012216 screening Methods 0.000 abstract description 15
- 239000012634 fragment Substances 0.000 abstract description 14
- 210000002966 serum Anatomy 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract description 5
- 238000012163 sequencing technique Methods 0.000 abstract description 5
- 230000007910 cell fusion Effects 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000002163 immunogen Effects 0.000 abstract description 4
- 238000005259 measurement Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 22
- 241000700605 Viruses Species 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 102100031673 Corneodesmosin Human genes 0.000 description 11
- 101710139375 Corneodesmosin Proteins 0.000 description 11
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 10
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 208000001528 Coronaviridae Infections Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 8
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000000683 abdominal cavity Anatomy 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 241000282836 Camelus dromedarius Species 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101150010882 S gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 101150013191 E gene Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 2
- 101710145006 Lysis protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 1
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 1
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 1
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 1
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 1
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 1
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 1
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 1
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 1
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 1
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 1
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 1
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 1
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 1
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 1
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000020248 camel milk Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical class [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了抗MERS‑CoV的单克隆抗体及其制备方法于应用,将MERS‑CoV病毒的s蛋白的部分片段作为免疫原免疫小鼠,通过细胞融合和经过杂交瘤细胞的筛选,初步获得具有较高效价及敏感性的单克隆抗体细胞株。通过棋盘法筛选能够实现最佳配对的单克隆抗体,并对获得的最佳配对抗体进行测序列测定,进一步获得了抗体的重链以及轻链可变区序列。建立一种基于酶联免疫反应(ELISA)的双抗体夹心检测方法用于检测MERS‑CoV。采用所述配对抗体建立的双抗夹心法可以将MERS‑CoV感染者与SARS感染者以及正常阴性血清区分,并且对于临床样本的检测具有较高的符合率。采用本发明制备的单克隆抗体,可以应用于血清样本中MERS‑CoV的检测,以辅助MERS的诊断和预防,具有特异性强、灵敏度高、准确性好等优点。
Description
技术领域
本发明属于生物检测领域,具体涉及一种抗MERS-CoV单克隆抗体及其应用,以及基于所述单克隆抗体建立的ELISA检测方法。
背景技术
中东呼吸综合征(MERS)是由中东呼吸综合症冠状病毒(MERS corona virus,MERS-CoV)感染引起的一种急发传染性呼吸系统疾病,2012年最早在约旦和沙特发现。
MERS-CoV是一种人兽共患病病毒,单峰骆驼是主要的动物宿主和传播给人类的主要来源。该病毒在单峰骆驼中不会引起重大疾病,但通过无保护措施的鼻、眼分泌物、粪便以及牛奶和尿液与该病毒接触,已多次传播给人类。这种病毒也可能存在于受感染动物的器官和肉中。这种人兽共患病最常发生在阿拉伯半岛国家;目前在非洲、中东和南亚大部分地区的单峰骆驼体内也都发现了这种病毒。
患者主要表现为发热、咳嗽和气短,肺炎常见,偶见腹泻等胃肠炎症状,严重者可发展为肾衰竭后死亡。该病的潜伏期为2至14天,典型表现为急性呼吸道感染,起病急,高热(39℃~40℃),可伴有畏寒、寒战、咳嗽、胸痛、头痛、全身肌肉关节酸痛、乏力、食欲减退等症状。目前尚无可用的疫苗和特异性治疗方法,主要采用对症治疗和支持性疗法。虽然该病最初发生在中东地区,但随着贸易、旅游、宗教等的活动的开展,逐渐蔓延到欧洲、非洲、亚洲和北美洲等27个国家。
MERS-CoV的形态结构与分类学冠状病毒科下分α、β、γ和δ4个属,病原学调查确认病原体为一种新的冠状病毒,命名为MERS冠状病毒(MERS-CoV)。前2个属感染人及其他哺乳动物等,后2个属主要感染禽类等脊椎动物。冠状病毒形态结构在电镜下大同小异,多表现为日冕状或皇冠状,多为圆形或椭圆形,表面呈突起状,大的突起主要是刺突蛋白,小的有膜成分在内。
MERS-CoV是单股正链RNA病毒。全基因组一般超过30000个核苷酸,不同株间略有差别,基因组分析分为A、B两亚群,但A亚群只有少数株数,主要都在B亚群。
全基因组编码16种非结构蛋白和4种主要结构蛋白。其中以三聚体形式锚定在囊膜上的刺突糖蛋白(Spike,S)是免疫原性最强的结构蛋白,在病毒吸附,决定病毒毒力和组织嗜性,以及诱导保护性免疫等方面发挥重要作用。S蛋白全长共含有1353个氨基酸,由膜外N端的S1亚基和近膜端的S2亚基组成。研究表明,S1亚基能与宿主细胞表面的DPP4受体结合进而介导病毒进入宿主细胞。MERS-CoV的4个结构蛋白S、M、E、N中,以S蛋白最为重要。S蛋白以三聚体形式存在,以机体的二肽酶(DPP4;又称为CD26)为受体进入细胞,开始进行病毒的生命循环。DPP4主要存在于多种哺乳动物的肾、小肠、肝和前列腺等脏器的上皮细胞表面,在单峰骆驼中,DPP4存在于上呼吸道上皮细胞表面,而在人类中,DPP4则多在肺泡表面表达。S蛋白在进入DPP4前,裂解成S1和S2两个亚基,S1与DPP4的受体结合域(RBD)结合,此后S2细胞与MERS-CoV膜融合,促使病毒核酸进入细胞。
S蛋白既存在可使病毒遗传物质进入机体的RBD,又是进入宿主细胞的主要免疫原,因此是研制药物的靶点和候选疫苗的主要目标蛋白。MERS-CoV能感染多种动物,与DPP4能改变与S蛋白结合介面的静电荷有关。其他3种蛋白M、E、N及辅助蛋白,M主要在病毒的外层,起维护病毒形态的作用,与S蛋白相互作用,在E蛋白的辅助下,病毒RNA能进入细胞浆进行复制;E蛋白具有较多的嗜水域,为主在双脂膜的内层,并和N衣壳蛋白相连,在病毒出芽生殖中起作用,N衣壳蛋白最主要的作用在于裹胁、保护病毒的RNA;辅助蛋白的作用可能与病毒的致病性有关,现已明确,包括M蛋白在内,ORF4A,ORF4B和ORF5编码的蛋白是I型干扰素的拮抗剂。
目前认为传染源与带MERS病毒的骆驼有关,因此与骆驼有密切接触的人群(饲养人员、农场工人、屠宰场工人和兽医等)感染可能性较大,赴中东旅游接触了骆驼或其分泌物、饮用未消毒骆驼奶的游客也有可能感染。与病例有密切接触的医务人员、家属感染MERS-CoV的风险均较高。另外,对现有感染MERS病例研究显示,病例的平均年龄为50岁,76%的MERS病例至少存在一种基础性疾病,包括慢性肾衰、糖尿病、心脏病等,且死亡病例与其他MERS病例比较,其基础疾病患病率更高(86.8%VS42.4%,P<0.001)。因此,患有糖尿病、慢性肺部疾病、肾衰或者免疫力低下的人群也被认为是感染MERS-CoV的高风险人群。
MERS的诊断需要结合临床特点、流行病学因素和在呼吸道中检测到病毒。检测方法主要有病毒核酸检测和血清学检测。一种实时RT-PCR方法是通过目标区域上游的E基因(upE)或开放读取框来实现监测的。E基因用来筛选,而开放读取框1b用来确认;另一种实时RT-PCR方法是以核壳蛋白基因为目标来筛选和确认的。当两种实时RT-PCR方法的结果不一致时,合适的RT-PCR扩增子排序可以帮助确认结果。但是,血清学样本的结果需要谨慎解释,可能会由于交互效应而与其他冠状病毒感染混淆。
通常,血清学检测适用于在无法开展核酸扩增时在《国际卫生条例》下应用血清学来定义MERS-CoV感染病例、持续性暴发调查中的部分调查及血清学专项调查。应用血清学确认MERS-CoV感染的方法较多,其中2项免疫荧光试验和1项血清中和试验在德国用于确诊病例密切接触者的筛查,并在沙特阿拉伯用于人群血清流行率的调查;1项利用蛋白质芯片技术的提示具有较高的特异度;此外,还有2项ELISA试验也被报道用于MERS-CoV的检测。
MERS-CoV的准确检测是预防和后续治疗的基础,本研究旨在开发出一种对MERS-CoV具有高亲和性和高特异性的单克隆抗体,通过棋盘法筛选获得最佳配对的单克隆抗体,建立一种基于酶联免疫反应(ELISA)的双抗体夹心检测方法,以用于准确检测各种样品中MERS-CoV的含量,以辅助MERS的诊断和预防。
发明内容
本发明公开了抗MERS-CoV单克隆抗体,所述单克隆抗体的轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:7、8和9所示;和所述单克隆抗体的重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:18、19和20所示。
本发明公开了单克隆抗体,所述单克隆抗体的轻链可变区的氨基酸序列分别如SEQ ID NO:6所示;和所述单克隆抗体的重链可变区氨基酸序列分别如SEQ ID NO:17所示。
本发明公开了抗MERS-CoV单克隆抗体,所述单克隆抗体的重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:18、19和20所示;和所述单克隆抗体的轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:7、8和9所示;或,所述单克隆抗体的重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:23、24和25所示;和所述单克隆抗体的轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:12、13和14所示。
本发明公开了单克隆抗体,所述单克隆抗体的重链可变区氨基酸序列分别如SEQID NO:17所示;和所述单克隆抗体的轻链可变区的氨基酸序列分别如SEQ ID NO:6所示;或,所述单克隆抗体的重链可变区氨基酸序列分别如SEQ ID NO:22所示;和所述单克隆抗体的轻链可变区的氨基酸序列分别如SEQ ID NO:11所示。
本发明公开了所述的单克隆抗体,还包括恒定区,所述单克隆抗体的重链的恒定区为IgG1、IgG2、IgG3或IgG4的任意一种;所述单克隆抗体的轻链的恒定区为κ型或λ型。
本发明公开了编码所述的单克隆抗体的核苷酸分子。
本发明公开了所述的核苷酸分子,所述编码单克隆抗体重链的核苷酸分子序列如SEQ ID NO:16所示,所述编码单克隆抗体轻链的核苷酸分子序列如SEQ ID NO:5所示;或,所述编码单克隆抗体重链的核苷酸分子序列如SEQ ID NO:21所示,所述编码单克隆抗体轻链的核苷酸分子序列如SEQ ID NO:10所示。
本发明公开了表达载体,所述表达载体包含所述的核苷酸分子。
本发明公开了细胞,所述细胞包含所述的载体。
单克隆抗体,其特征在于,所述单克隆抗体由权利要求7所述的细胞表达获得。
本发明公开了所述的单克隆抗体在制备检测MERS-CoV的试剂盒中的用途。
一种检测MERS-CoV的试剂盒,所述试剂盒包括所述的单克隆抗体。
本发明公开了所述的试剂盒,所述试剂盒还包括终止液。
本发明公开了所述的试剂盒,所述试剂盒为ELISA检测试剂盒或胶体金检测试剂盒。
优选的,所述检测试剂盒还包括标准品。
优选的,所述试剂盒可以应用于MERS-CoV的定量检测。
优选的,所述试剂盒可以应用于MERS-CoV的快速检测。
本发明公开了抗MERS-CoV的单克隆抗体及其制备方法,将MERS-CoV病毒的s蛋白的部分片段作为免疫原免疫小鼠,通过细胞融合和经过杂交瘤细胞的筛选,初步获得具有较高效价及敏感性的单克隆抗体细胞株。通过棋盘法筛选能够实现最佳配对的单克隆抗体,并对获得的最佳配对抗体进行测序列测定,进一步获得了抗体的重链以及轻链可变区序列。建立一种基于酶联免疫反应(ELISA)的双抗体夹心检测方法用于检测MERS-CoV。采用所述配对抗体建立的双抗夹心法可以将MERS-CoV感染者与SARS感染者以及阴性血清区分,并且对于临床样本的检测具有较高的符合率。采用本发明制备的单克隆抗体,可以应用于血清样本中MERS-CoV的检测,以辅助MERS的诊断和预防,具有特异性强、灵敏度高、准确性好等优点。
附图说明
图1为重组质粒pET-28a-S酶切电泳图,其中1为重组质粒图,2为酶切后的质粒和S基因片段。
图2为表达的MERS-S蛋白,纯化后的电泳检测图。
图3为筛选的5个杂交瘤细胞分离纯化后的抗体的电泳图,其中,1为杂交瘤2C7,2为杂交瘤4D9,3为杂交瘤6E4,4为杂交瘤7G5,5为杂交瘤8F10。
图4为棋盘法筛选最佳配对抗体的柱状结果图。
图5为棋盘法筛选最佳配对抗体的曲线结果图。
图6为ELISA方法中不同包被浓度以及标记浓度的优化检测结果图。
具体实施方式
以下实施例进一步说明本发明的内容,但不应理解为对本发明的限制。在不背离本发明精神和实质的情况下,对本发明方法、步骤或条件所作的修改或替换,均属于本发明的范围。
若未特别指明,实施例中所用的技术手段为本领域技术人员所熟知的常规手段。
实施例1主要试剂及培养基的配制
1.LB培养基:胰蛋白胨1g、酵母粉0.5g、NaCl 1g、,加100mL去离子定容,高压灭菌,4℃保存备用。
2. 10%SDS:SDS 5g,加去离子水50mL充分溶解,4℃保存。
3.完全1640培养液:含20%胎牛血清、1%双抗和1%L-G的基础1640培养液,4℃保存备用;
4.HAT培养液:含2%HAT的完全1640培养液。
5.HT培养液:含1%HT的完全1640培养液。
实施例2MERS-CoV的S蛋白的表达纯化
1.扩增引物设计以及表达载体的构建
首先采用抗原表位预测软件,对于NCBI上公开的MERS-CoV的S蛋白进行分析,选取含有相应的抗原优势表位的片段,并进一步设计引物扩增编码MERS-CoV的S蛋白的基因片段,由生物科技有限公司合成的S基因作为模板,采用PCR扩增、纯化、回收S基因片段,通过BamHⅠ和XhoI限制性内切酶双酶切后插入pET-28a表达载体,构建pET-28a-S基因重组质粒。
其中,上游引物:5’-ggattcgaaagttacgttgatgtag-3’(SEQ ID NO:1),(包含BamHⅠ酶切位点);
下游引物:5’-ctcgagtcatctgcgtatataacca-3’(SEQ ID NO:2),(包含XhoI酶切位点),扩增片段如SEQ ID NO:3:大小为963bp(未包含酶切位点)。重组质粒pET-28a-S为模板,利用合成的引物进行PCR。扩增产物经1%琼脂糖凝胶电泳鉴定正确后进行目的片段的回收。用BamHⅠ和XhoI双酶切重组质粒pET-28a-S,得到约为960bp(S片段基因)和约5300bp的质粒片段,重组质粒鉴定正确,质粒酶切的电泳图片参见图1。
2.MERS-CoV-S重组蛋白的表达与纯化
将构建的重组质粒转化大肠杆菌BL21(DE3),筛选获得阳性转化菌株后备用。
取20μl重组菌株BL21(DE3)/pET-28a-S接种于20ml LB液体培养基(含50μg/mLKan)中,37℃、180r/min培养。次日取少量菌液转接到200mlLB液体培养基(含50μg/mL Kan)中,37℃、180r/min培养至OD600达到0.5-0.6时,加入终浓度为0.8mM的IPTG,25℃、200r/min诱导培养10小时。4℃、8000r/min离心6分钟收集菌体,加入10mL PBS缓冲液重悬菌体,经超声波破碎处理后,4℃、8500r/min离心6分钟收集菌体,收集上清液,经镍柱基质纯化后,取5微克重组蛋白进行SDS-PAGE检测。电泳检测结果参见图2。
实施例3抗MERS-CoV的杂交瘤细胞的筛选与制备
1.小鼠免疫与抗血清的检测
将纯化获得重组MERS-CoV-S蛋白稀释后,0.1%(V/V)甲醛灭活24小时后,作为免疫原免疫小鼠。采取皮下多点注射的方式对8周龄BALB/c小鼠(共5只)进行免疫(50μg/只),免疫3次。
初次免疫使用弗氏完全佐剂与目的蛋白等体积混合并充分乳化;第2次和第3次免疫用弗氏不完全佐剂等体积混合并乳化。其中,第3次免疫的过程中,有两只小鼠的生存状况不佳,出现厌食消瘦状况,因此,将这两只免疫小鼠舍弃,仅保留另外3只小鼠继续试验。第3次免疫后第10天取小鼠尾静脉血,通过间接ELISA法检测抗血清效价,检测结果参见表1,从ELISA的初步检测结果来看,编号为2的小鼠免疫效果最好。因此,后续将选择效价高的2号小鼠用于细胞融合。
表1:免疫小鼠多抗血清效价的测定
2.细胞融合与杂交瘤细胞的筛选
将SP2/0瘤细胞从液氮罐中复苏后,加入RPMI1640培养基于离心瓶中混合均匀,置于二氧化碳培养箱中培养备用。
取未经免疫的清洁级BALB/c小鼠一只,摘眼球采血后即把小鼠拉颈处死,剪开小鼠腹膜。吸取冷的HAT培养基,打入小鼠腹腔,轻轻挤压小鼠腹腔回抽出含有饲养细胞的培养液。
取初步测定血清效价较好的第2只免疫后的BALB/c小鼠,摘眼球拉颈处死小鼠,取其脾脏,并对脾脏进行研磨,之后取5mL预热的GNK洗液缓慢冲洗,制成单细胞悬液。
用PEG1500将分离得到的脾细胞与提前复苏的SP2/0骨髓瘤细胞按3:1至5:1的比例融合,融合后使用HAT及HT培养基进行换液培养。培养约4d后吸取细胞培养上清液,将表达的MERS-S蛋白包被酶联免疫96孔板,通过间接ELISA筛选阳性杂交瘤细胞,并进一步采用有限稀释法进行亚克隆,转移至24孔细胞培养板进行扩大培养。待细胞长至1/2孔底时,取上清测其效价值和敏感性,筛选获得5株具有较高效价(达到1:2.56X105)及敏感性杂交瘤细胞株,其中6E4的敏感性更好(表2)。
表2:筛选的杂交瘤的效价及敏感性
杂交瘤编号 | 效价 | 敏感性 |
2C7 | 1:2.56X10<sup>5</sup> | 1.056ng/mL |
4D9 | 1:2.56x10<sup>5</sup> | 0.723ng/mL |
6E4 | 1:2.56x10<sup>5</sup> | 2.314ng/mL |
7G5 | 1:2.56x10<sup>5</sup> | 0.561ng/mL |
8F10 | 1:2.56x10<sup>5</sup> | 0.432ng/mL |
实施例4抗MERS单克隆抗体的大量制备与纯化
1.腹水的制备
用经产的BALB/C母鼠腹腔大量的制备单克隆抗体,用经产母鼠是因为其腹腔内的空间较大,便于产生更多的抗体。首先在母鼠腹腔内注射1ml灭菌的液体石蜡。约7天后,用纯1640培养基清洗并悬浮杂交瘤细胞(尽量去除杂蛋白和FBS),计数,并用500ul纯1640培养基重悬约5×106个细胞,注射到母鼠的腹腔中。
大约7-10天后母鼠腹腔中已出现大量的腹水,要立即抽取收集。用较粗的针头(12号针头)从腹股沟处插入腹腔内,后使腹水自然流出并用离心管收集。3-5天后,母鼠的腹腔会继续变大,可继续收集腹水,收集的腹水5000r/min离心15min,上清上层的油状不溶物质弃掉,取上清,保存于-20℃中。
2.单克隆抗体的纯化
取出保存的腹水,加入3倍体积的醋酸盐缓冲液,充分混合均匀后用NaOH溶液调pH至4.3。测量上述溶液总体积,按0.025mL/mL的量缓慢加入合适体积的辛酸,4℃缓慢搅拌45min。4℃,5000rpm离心1h,收集中间液体并使用滤纸过滤。加入1/10体积的0.2M的PBS,充分混合均匀后调pH至7.4。按照0.2778g/mL的量在上述溶液中加入固体硫酸铵,4℃缓慢搅拌30min。4℃,8000rpm离心1h,弃上清,使用0.02M的PBS充分溶解沉淀。4℃条件下透析过夜并换液2-3次。收取透析液,-20℃保存备用。将纯化后的抗体采用电泳检测,其中5株杂交瘤在进行抗体大量制备纯化后的电泳结果参见图3。纯化后的抗体含有两条特异性的条带,与IgG的重链和轻链的大小也一致。
实施例5棋盘法筛选最佳配对抗体
用碳酸盐缓冲液(CBS0.05mol/L,pH9.6)作为稀释单抗介质,稀释纯化获得2C7、4D9、6E4、7G5、8F10这5株单抗分别稀释到约2μg/mL,按照100μL/孔的规格加入ELISA板,4℃过夜包被。弃去并在纸上拍尽包被液,ELISA板用PBST(PBS pH 7.4,0.05%Tween-20)清洗2-3次,弃去孔中液体,晾干得到抗体包被板。
采用改良的过碘酸钠法将单克隆抗体标记HRP,按照1:5000的稀释倍数之后,作为酶标二抗使用
棋盘滴定法实验,每种包被抗体制备的包被板分别和其它4种抗体的HRP标记物配对,检测不同浓度的MERS-S抗原。具体操作:包被板孔中加入不同浓度的MERS-S抗原,温育后洗涤2-3次。每孔加入HRP标记的抗MERS单克隆抗体,温育后洗涤2-3次。加入底物TMB进行显色后,加硫酸中止反应,置酶标仪(OD450nm)中测定A值。筛选结果参见柱状图4以及曲线图图5。
根据筛选的图4以及图5的结果所表现出来的线性关系以及检测最低限及最高限之间的数值关系可知,抗体6E4和7G5之间进行配对的检测效果较好,而抗体2C7和4D9之间进行配对的检测效果较好,并且抗体6E4和7G5之间的配对检测效果优于抗体2C7和4D9之间的配对。
实施例6单克隆抗体6E4和7G5可变区基因的获取
分别提取杂交瘤细胞株6E4和7G5的总RNA,并根据BIO TEC公司逆转录试剂盒的操作方法,分别反转录制备获得对应的cDNA序列。
根据已知的小鼠抗体轻链恒定区序列,设计相应的扩增引物:5’-TCACTGCCATCAATCTTCCAC-3’,SEQ ID NO:4)和试剂盒中的接头引物进行PCR扩增,获得相应的杂交瘤分泌的抗MERS-CoV鼠单克隆抗体轻链片段,并于pGEM-T载体构建后测序。
测序后获得抗MERS-CoV鼠单克隆抗体6E4轻链可变区基因序列为:gatattcaggaaacccagacccgcagcgtgctgagcgcggcgctgggcagccgcgtgaccattagctgcagcatggatattgcgaactatgtgaacgaatatcagtggtatcagagcccgaaaccggattttgatgtgaaactgagcatttatgaagtgctgatttatcgcagcgtgcgcctgcagagcggcgtgccgagccgctttagcaaaaaaggcagcctggatgattatagcctgaccattagctgctttgaaccggaagatgtggaaatttattgcaacgattgccagattctgggcagcgaactgccggaatttggcgattttaccaaaattgaaattctgcgc(SEQ ID NO:5)。
抗MERS-CoV鼠单克隆抗体6E4轻链可变区的序列为:
DIQETQTRSVLSAALGSRVTISCSMDIANYVNEYQWYQSPKPDFDVKLSIYEVLIYRSVRLQSGVPSRFSKKGSLDDYSLTISCFEPEDVEIYCNDCQILGSELPEFGDFTKIEILR(SEQ ID NO:6所示)。
按照抗体CDR结构分析网站中对于抗体的CDR分析定义方法,获得抗MERS-CoV鼠单克隆抗体6E4的轻链可变区的CDR序列,其中:CDR1序列为:SMDIANYVNEYQ(SEQ ID NO:7);CDR2序列为:EVLIYRSVRLQS(SEQ ID NO:8);CDR3序列为:NDCQILGSELPE(SEQ ID NO:9)。
获得抗MERS-CoV鼠单克隆抗体7G5轻链可变区基因序列为:gatattagcctgacccgcagcccgagcaccctgagcgcgaccccgcaggaaagcgtgagcctgagctgcaaacagctgattagcagctatctgatgtggacccagtggtatcagagcaaaagccatgaaagcctggaactgaccgaaaaagtggaactgatttatagcaacagccatctgcataccggcattccgtttagctttagcggcgatgatagcggcaccgatttttttctgaaagtgaacgtgaacagcaccgaagattttggcgaatatttttgcagctgccaggatcagaacaccagcgaacgcggcgattttggccaggcgaccaaactgctggaaaaa(SEQ ID NO:10);
抗MERS-CoV鼠单克隆抗体7G5对应的轻链可变区的序列为:
DISLTRSPSTLSATPQESVSLSCKQLISSYLMWTQWYQSKSHESLELTEKVELIYSNSHLHTGIPFSFSGDDSGTDFFLKVNVNSTEDFGEYFCSCQDQNTSERGDFGQATKLLEK(SEQ ID NO:11)。
按照抗体CDR结构分析网站中对于抗体的CDR分析定义方法,获得抗MERS-CoV鼠单克隆抗体7G5的轻链可变区的CDR序列,其中:CDR1序列为:KQLISSYLMWTQ(SEQ ID NO:12);CDR2序列为:VELIYSNSHLHT(SEQ ID NO:13);CDR3序列为:SCQDQNTSERGD(SEQ ID NO:14)。
根据已知的小鼠抗体重链恒定区序列,设计相应的扩增引物:5’-CTCAGGGAARTARCCYTTGAC-3’,SEQ ID NO:15)和试剂盒中的接头引物进行PCR扩增,获得相应杂交瘤分泌的抗MERS-CoV鼠单克隆抗体重链片段,并于pGEM-T载体构建后测序。
获得抗MERS-CoV鼠单克隆抗体6E4重链可变区基因序列为:gaagtggatctgagcgaaagcctgggcggccaggtgaaagtgaccggcagcctgaaactggatgaagcggcgagcggcagcatgcatggcggcgatgtgaaagaaggcgcgagcctgtggctgtgggtgcgcgtgaccccggaaattgaactggaatggcgcgatgcgcagggcgtggcgtttattagcgcgggcgaaagcagcacctatcgctttaccaccagccgcgataacgcgcgcagcgatcgctatctgcagatgagcgaactgcgcaaactggataccgcgtttatttattgcggccgctatcgcgtgaccctgagcaccctgcaggaatatagctggggccagggcgattgggtgaccaccgatgcg(SEQ ID NO:16)。
抗MERS-CoV鼠单克隆抗体6E4的重链可变区的序列为:
EVDLSESLGGQVKVTGSLKLDEAASGSMHGGDVKEGASLWLWVRVTPEIELEWRDAQGVAFISAGESSTYRFTTSRDNARSDRYLQMSELRKLDTAFIYCGRYRVTLSTLQEYSWGQGDWVTTDA(SEQ ID NO:17);
按照抗体CDR结构分析网站中对于抗体的CDR分析定义方法,获得抗MERS-CoV鼠单克隆抗体6E4的重链可变区的CDR序列,其中:CDR1序列为:SMHGGDVKEGASLWL(SEQ ID NO:18);CDR2序列为:QGVAFISAGESST(SEQ ID NO:19);CDR3序列为:YRVTLSTLQEYS(SEQ ID NO:20)。
获得抗MERS-CoV鼠单克隆抗体7G5重链可变区基因序列为:gaagtgcagggccaggtgagcggcctgaaactggtggtggaaggcgcgagcgtgctgaaaagctgcaccagcaccggctttctgagcggcatgggcctggtgatgccgggcggcagcaaccatagctgggtgcaggaagtgccggaaattgtgctggaatggagcggcgattggagcgcgaactatagccaggatggcctgattaccagcaaagcgaccgcgagcgcggataccaccgatagcaccgcgtatctgcagctgagcgaatttgatagcgaagataccgcggtgagctttagctgcgcgagcaactggctgatgctgtatatggcgagcctgaactggggccagggcgaagatgataccgtgcagagc(SEQ ID NO:21)。
抗MERS-CoV鼠单克隆抗体7G5的重链可变区的序列为:
EVQGQVSGLKLVVEGASVLKSCTSTGFLSGMGLVMPGGSNHSWVQEVPEIVLEWSGDWSANYSQDGLITSKATASADTTDSTAYLQLSEFDSEDTAVSFSCASNWLMLYMASLNWGQGEDDTVQS(SEQ ID NO:22)。
按照抗体CDR结构分析网站中对于抗体的CDR分析定义方法,获得抗MERS-CoV鼠单克隆抗体7G5的重链可变区的CDR序列,其中:CDR1序列为:LSGMGLVMPGGSNHS(SEQ ID NO:23);CDR2序列为:DWSANYSQDGLIT(SEQ ID NO:24);CDR3序列为:SNWLMLYMASLN(SEQ ID NO:25)。
实施例7配对抗体的使用的浓度优化
使用不同浓度(0.5、1、2、3、4μg/mL)的抗MERS-CoV单抗6E4包被96孔微孔板(包被液为CB),封闭过夜。弃去孔中液体,晾干备用。
包被板孔中加入不同浓度(50pg/mL、100pg/mL、200pg/mL、500pg/mL、1000pg/mL)的表达的MERS-CoV-S抗原,37℃温育1小时,洗涤3次。每孔加入分别稀释1:1000、1:2000、1:5000、1:10000的HRP标记的抗MERS-CoV单抗7G5,反应1小时后,洗涤2-3次。加入底物DAB进行显色后,加硫酸中止反应,置酶标仪中(于490nm处)测定A值。检测结果见图6。优化后的单抗6E4的优化的包被浓度是2μg/mL,HRP标记单抗7G5的优化稀释浓度是1:5000。
实施例8抗体的特异性检测
采用实施例7中优化后的抗体的浓度,制备获得相应的包被浓度以及标记浓度的单抗ELISA检测试剂盒,并对临床样本进行检测,临床样本包括:10份阴性血清、10份MERS-CoV患者感染血清以及10份SARS感染者血清,上述血清分别采用对应的MERS-CoV以及SARS的RT-PCR方法进行确认。采用上述ELISA试剂盒检测,检测结果的OD值表明,10份MERS-CoV患者感染血清明显高于另外20份血清,采用所述试剂盒能够特异性的区分出MERS-CoV患者,检测的具体结果参见表3。
表3:ELISA试剂盒检测30份血清样本的检测结果
编号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
阴性血清 | 0.036 | 0.027 | 0.031 | 0.028 | 0.157 | 0.239 | 0.205 | 0.233 | 0.286 | 0.217 |
MERS-CoV患者 | 2.816 | 3.014 | 1.957 | 2.068 | 2.374 | 2.854 | 2.883 | 2.749 | 1.764 | 2.551 |
SARS患者 | 0.087 | 0.139 | 0.065 | 0.113 | 0.027 | 0.210 | 0.187 | 0.097 | 0.432 | 0.312 |
实施例9抗体的准确性检测
采用实施例7中优化后的抗体的浓度,制备获得相应的包被浓度以及标记浓度的单抗ELISA检测试剂盒,并对临床样本进行检测,临床样本共计60份。阳性判断标准为,检测的OD值大于实施例8的表3中10份阴性血清测定的平均OD值的2.5倍以上。检测得到26份阳性样本,以及35份阴性样本,将检测结果采用RT-PCR检测方法进行比较,发现本申请的夹心法的阳性符合率为96.29%,具有较高的阳性符合率。准确性检测结果参见表4。
表4:临床样本的准确性检测
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明技术原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.抗MERS-CoV单克隆抗体,其特征在于,所述单克隆抗体的轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:7、8和9所示;和所述单克隆抗体的重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:18、19和20所示。
2.根据权利要求1所述的单克隆抗体,其特征在于,所述单克隆抗体的轻链可变区的氨基酸序列分别如SEQ ID NO:6所示;和所述单克隆抗体的重链可变区氨基酸序列分别如SEQID NO:17所示。
3.根据权利要求1-2任一所述的单克隆抗体,还包括恒定区,所述单克隆抗体的重链的恒定区为IgG1、IgG2、IgG3或IgG4的任意一种;所述单克隆抗体的轻链的恒定区为κ型或λ型。
4.编码权利要求1-3任一权利要求所述的单克隆抗体的核苷酸分子。
5.根据权利要求4所述的核苷酸分子,其特征在于,所述编码单克隆抗体轻链的核苷酸分子序列如SEQ ID NO:5所示,所述编码单克隆抗体重链的核苷酸分子序列如SEQ ID NO:16所示。
6.表达载体,其特征在于,所述表达载体包含权利要求4或5所述的核苷酸分子。
7.细胞,其特征在于,所述细胞包含权利要求6所述的载体。
8.单克隆抗体,其特征在于,所述单克隆抗体由权利要求7所述的细胞表达获得。
9.权利要求1-3任一权利要求所述的单克隆抗体在制备检测MERS-CoV的试剂盒中的用途。
10.一种检测MERS-CoV的试剂盒,其特征在于,所述试剂盒包括权利要求1-3任一权利要求所述的单克隆抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210694642.0A CN114989295B (zh) | 2022-06-17 | 2022-06-17 | 抗MERS-CoV单克隆抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210694642.0A CN114989295B (zh) | 2022-06-17 | 2022-06-17 | 抗MERS-CoV单克隆抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114989295A true CN114989295A (zh) | 2022-09-02 |
CN114989295B CN114989295B (zh) | 2023-05-23 |
Family
ID=83035876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210694642.0A Active CN114989295B (zh) | 2022-06-17 | 2022-06-17 | 抗MERS-CoV单克隆抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114989295B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115724983A (zh) * | 2022-10-10 | 2023-03-03 | 宝船生物医药科技(上海)有限公司 | 一种针对抗csf1r单克隆抗体的抗独特型抗体及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210238261A1 (en) * | 2018-08-17 | 2021-08-05 | Industry Academic Cooperation Foundation, Hallym University | Monoclonal antibody against s protein of mers-coronavirus, and use of same |
CN113527446A (zh) * | 2021-07-14 | 2021-10-22 | 河南省农业科学院动物免疫学重点实验室 | 一种MERS-CoV S-RBD线性B细胞表位及其特异性识别单克隆抗体和应用 |
CN114106164A (zh) * | 2021-12-09 | 2022-03-01 | 杭州旭科生物技术有限公司 | 抗新型冠状病毒s蛋白的单克隆抗体及其应用 |
-
2022
- 2022-06-17 CN CN202210694642.0A patent/CN114989295B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210238261A1 (en) * | 2018-08-17 | 2021-08-05 | Industry Academic Cooperation Foundation, Hallym University | Monoclonal antibody against s protein of mers-coronavirus, and use of same |
CN113527446A (zh) * | 2021-07-14 | 2021-10-22 | 河南省农业科学院动物免疫学重点实验室 | 一种MERS-CoV S-RBD线性B细胞表位及其特异性识别单克隆抗体和应用 |
CN114106164A (zh) * | 2021-12-09 | 2022-03-01 | 杭州旭科生物技术有限公司 | 抗新型冠状病毒s蛋白的单克隆抗体及其应用 |
Non-Patent Citations (2)
Title |
---|
LANYING DU等: "MERS-CoV spike protein: a key target for antivirals" * |
王丽丽等: "针对中东呼吸综合征冠状病毒的全人源单克隆抗体的研究进展" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115724983A (zh) * | 2022-10-10 | 2023-03-03 | 宝船生物医药科技(上海)有限公司 | 一种针对抗csf1r单克隆抗体的抗独特型抗体及其应用 |
CN115724983B (zh) * | 2022-10-10 | 2023-09-19 | 宝船生物医药科技(上海)有限公司 | 一种针对抗csf1r单克隆抗体的抗独特型抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114989295B (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Song et al. | Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines | |
CN112225797B (zh) | 一种抗SARS-CoV-2核衣壳蛋白的单克隆抗体及应用 | |
CN111239394B (zh) | 一种基于混合抗原快速检测新型冠状病毒抗体试剂盒 | |
CN110964102B (zh) | 能同时与犬、猫、水貂细小病毒结合的单克隆抗体、其可变区序列、杂交瘤细胞株及应用 | |
Okumura et al. | Development of serological assays for Thottapalayam virus, an insectivore-borne Hantavirus | |
CN104862285B (zh) | 猪流行性腹泻病毒抗体捕获elisa检测方法及应用 | |
CN102021147B (zh) | 引起严重急性呼吸道综合征(sars)的新型人病毒及其应用 | |
CN105296441B (zh) | 一种牛病毒性腹泻病毒毒株及其应用 | |
US20090074781A1 (en) | Dengue virus peptide vaccine and methods of preparing and using the same | |
EP3534160A1 (en) | Method for the detection and classification of prrsv-infections in swine herds and diagnostic antigen compositions for such methods | |
CN113249333A (zh) | 一种分泌抗呼吸道合胞病毒单克隆抗体的杂交瘤细胞株rsvn4c3 | |
CN114989295B (zh) | 抗MERS-CoV单克隆抗体及其应用 | |
KR20080012449A (ko) | 뉴클레오캡시드 또는 스파이크 단백질을 이용한 사스진단방법 | |
CN113249334A (zh) | 一种分泌抗发热伴血小板减少综合征病毒单克隆抗体的杂交瘤细胞株sftsn5g12 | |
CN116970074A (zh) | 一种与非洲猪瘟病毒CD2v胞内蛋白结合的单克隆抗体及其应用 | |
Hierholzer et al. | Coronaviridae: the coronaviruses | |
CN107167606A (zh) | 多诊断试剂盒 | |
KR20120132227A (ko) | 다중 타입 구제역 바이러스 검출용 단일클론 항체 및 이를 이용한 구제역 바이러스 검출방법 | |
KR101080071B1 (ko) | 재조합 n 단백질에 대한 단클론 항체를 이용한 리프트계곡열 경합적 효소결합면역측정법 | |
CN115838421A (zh) | 靶向乙型流感病毒核蛋白的抗体及其应用 | |
CN113698474B (zh) | 一种非洲猪瘟多克隆抗体及非洲猪瘟抗原检测试纸条 | |
US20190240311A1 (en) | Pestivirus marker vaccine | |
CN113248578A (zh) | 新型冠状病毒(2019-nCoV)重组抗原及多克隆抗体 | |
AU666483B2 (en) | Stealth virus detection in the chronic fatigue syndrome | |
Schmidt et al. | Coronaviruses with special emphasis on first insights concerning SARS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |